Previous close | 6.40 |
Open | 6.40 |
Bid | 8.20 |
Ask | 8.50 |
Strike | 26.00 |
Expiry date | 2024-09-20 |
Day's range | 6.40 - 6.40 |
Contract range | N/A |
Volume | |
Open interest | 4 |
SAN DIEGO, June 18, 2024--Acadia Pharmaceuticals, Inc. (Nasdaq: ACAD) today announced that interim data from the open-label real-world LOTUS™ study will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting, being held this week in Westminster, Colorado. LOTUS is an ongoing, caregiver-reported study evaluating the efficacy and tolerability outcomes in patients with Rett syndrome treated with DAYBUE™ (trofinetide).
Key Insights ACADIA Pharmaceuticals' Annual General Meeting to take place on 29th of May Total pay for CEO Steve Davis...
SAN DIEGO, May 17, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on May 15, 2024, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 57,252 shares of common stock and 33,675 restricted stock units ("RSUs") to twenty-two new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ emplo